Division of Drug Information Webinars
Educational Webinars for Health Care Professionals and Students
FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) sponsors a series of educational webinars targeting the needs of health care professionals and students. The webinars cover a broad range of FDA drug regulation and medication safety topics. These focused webinars support FDA's mission of promoting and protecting public health through interaction and education to strengthen current and future partnerships and relationships with clinicians and researchers.
Continuing Education (CE) Credit
CE credit is available for our live and home study webinars. If you are a physician, physician assistant, nurse, pharmacist, or pharmacy technician, refer to the individual webinar listing for complete CME/AAPA/CNE/CPE/CPT/CPH information.
For more information
-
Visit the Division of Drug Information web site at: http://www.fda.gov/AboutDDI
-
Call us at: 1-855-543-3784 or 301-796-3400
-
Email us at: DDIWebinars@fda.hhs.gov
Upcoming Live CE Webinars
(Google Chrome (preferred) or Firefox 43 or higher)
- FDA Drug Topics: Overview of Expanded Access (EA) Program and EA eRequest Site – December 14, 2021
- FDA Drug Topics: Biosimilar and Interchangeable Biosimilars: Review of Scientific Concepts, Case Studies, and Resources – January 25, 2022
- FDA Drug Topics: Counseling Patients on Generic Drugs – February 22, 2022
NEW! Home Study CE Webinars
- Overview of Risk Evaluation and Mitigation Strategies (REMS) for Health Care Providers
- Project Facilitate: Oncology Expanded Access Program Update
- Orange Book: Frequently Asked Questions and Answers
- Biosimilar and Interchangeable Biological Products: An Updated Review of Scientific Concepts and Practical Resources
- Labeling Made Simple: The How, What, and Where of Drug Interactions in Prescribing Information
- An Overview of Naloxone and FDA’s Efforts to Expand Access
- CURE ID: Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19
- FDA’s Bad Ad Program
- Nitrosamine Impurities in Drugs: What Health Care Professionals Need to Know
- FDA Regulation of Color Additives in Drug Products
- An update to the FDA Adverse Event Reporting System (FAERS) Public Dashboard
- Tainted Products Marketed as Dietary Supplements
- FDA Drug Information Resources and Applicability to Health Care Professionals
- Research Funding Opportunities to Reduce Preventable Harm
- Building Confidence in Generic Narrow Therapeutic Index (NTI) Drugs
- 3D Printing in Drug Development and Emerging Health Care
- Drug Shortages: FDA Efforts, Current Challenges and Future Goals
Technical Requirements and Instructions for Home Study CE Webinars:
To access the course, users will need a computer with an Internet connection, and:
- Google Chrome (preferred),
- Firefox 43 or higher,
- Safari 9 or higher, or
- Any other W3C standards compliant browser
An HTML5 capable browser is required for video playback. Occasionally, other additional software may be required such as Microsoft PowerPoint or Adobe Acrobat Reader. Viewing on a desktop, laptop, or tablet is recommended.
This is a responsive course. Parts of the course may display differently across various devices and screen resolutions. Scrolling may be required in some instances.
Users are required to view the entire course before getting access to the post-test. To receive your certificate for CE credit or certificate of completion, you must complete the post-test and receive a score of 80 percent or better and complete an evaluation form.
Past 2021 Webinars
- FDA Drug Topics: Fraudulent Products – Hidden Ingredients and Unproven Claims in Products Marketed as Dietary Supplements – November 16, 2021
- FDA Drug Topics: How FDA and ISMP Utilize Medication Error Reports to Improve Drug Safety – October 19, 2021
- FDA Drug Topics: FDA’s Role in Postmarketing Drug Safety Surveillance - September 28, 2021
- FDA Drug Topics: Enhanced Drug Distribution Security: 2023 and Beyond - June 1, 2021
- FDA Drug Topics: Safety Labeling Changes for Leukotriene Receptor Antagonists and Decisions Behind a Boxed Warning - May 18, 2021
- FDA Drug Topics: FDA’s Office of Orphan Products Development (OOPD) – An Overview and Update - April 26, 2021
- FDA Drug Topics: The Ins and Outs of Prescription Drug Labeling – March 23, 2021
Past 2020 Webinars
- FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors – June 30, 2020 (Postponed from March 17, 2020)
- FDA Drug Topics: CURE ID: Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19 - June 9, 2020
Past 2019 Webinars
Past 2018 Webinars
- FDA Drug Topics: Biosimilar and Interchangeable Products in the U.S.: Scientific Concepts, Clinical Use, and Practical Considerations – December 10, 2018
- FDA Drug Topics: FDA's MedWatch Adverse Event Reporting Program - Opportunities to Collaborate - March 13, 2018
- FDA Drug Topics: An Overview of FDA's Expanded Access Program with a Focus on Individual Patient Expanded Access - February 20, 2018
- FDA Drug Topics: FDA Adverse Events Reporting System (FAERS) Public Dashboard - January 30, 2018
Past 2017 Webinars
- DDI Webinar Series: Overview of the Regulatory Framework and the Development and Approval of Biosimilar Products in the U.S. - December 5, 2017
- DDI Webinar Series: An Overview of FDA Resources - October 17, 2017
- DDI Webinar Series: Fluoroquinolone Safety Labeling Updates- April 4, 2017
- DDI Webinar Series: FDA Post-Marketing Drug Safety Surveillance- March 7, 2017
- DDI Webinar Series: "Collaborating with FDA- Get Involved with FDA's MedWatch Adverse Event Reporting Program" - February 7, 2017
ResourcesForYou
To view the webinars, copy and paste the web address starting with https:// into a web browser.